Webinar in French on Wednesday November 15, 2023 at 11:00 a.m. CET
Pursuit of an ambitious clinical development strategy to create a world leader in phage therapy targeting high value-added indications
Treatment of more than 90 patients suffering from osteoarticular infection on severe and resistant hip or knee prosthesis (PJI) within the framework of the Compassionate Access Authorization
Cash and cash equivalents amounting to €15.6 million ($16.5 million) as of September 30, 2023
Lyon (France) and Cambridge (MA, US), November 14, 2023 – 10:05 p.m. CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments against severe resistant bacterial infections, today provides an update on its activities and presents its financial results for the third quarter of 2023.
If you wish to receive all of the company’s financial communications in real time, you can register directly by email to the following address: [email protected]